Mayne Pharma itself has not been acquired as a whole entity; rather, it operates as an independent, publicly listed corporation on the Australian Securities Exchange. However, throughout its extensive corporate history, the enterprise has actively executed numerous strategic acquisitions and divestitures—such as acquiring various product portfolios from major pharmaceutical firms like Teva, Allergan, and GSK, while simultaneously divesting non-core business segments like its Metrics contract services unit—to optimize its focus on specialty branded and generic growth segments.